Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions, announced that its CEO, Michael Halstead, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference, scheduled for September 14-16, 2026, in New York City, is a key event for the investment community, drawing attention to emerging biotech companies.
The fireside chat is set to be webcast live on September 14 at 9 a.m. EDT, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website. This appearance provides a platform for Halstead to discuss the company's strategic direction and recent milestones, particularly the progress of its lead asset, HLP003, which is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD). HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA), a status that underscores its potential to address a significant unmet need in mental health care.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is dedicated to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's pipeline includes HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder, as well as an extensive research portfolio of investigational NSAs. These efforts aim to provide durable improvements in mental health outcomes, potentially transforming the treatment landscape for depression and anxiety.
The H.C. Wainwright conference is a notable venue for Helus Pharma to engage with investors and industry stakeholders, especially given the growing interest in psychedelic-inspired therapies and the broader mental health market. The company's participation highlights its commitment to advancing its clinical programs and communicating its progress to the financial community.
For investors and followers of the company, the webcast will offer insights into Helus Pharma's strategic priorities and the potential impact of its research. The company operates in Canada, the United States, the United Kingdom, and Ireland, and continues to expand its footprint in the mental health sector. Updates and additional information are available on the company's newsroom at https://ibn.fm/HELP.
This announcement comes at a time when mental health treatments are evolving, with a shift toward more targeted and rapidly acting therapies. Helus Pharma's focus on serotonergic agonists could position it favorably in this growing market. The company's participation in the conference is a strategic move to showcase its clinical advancements and attract potential partnerships or investment.
As the conference approaches, interested parties can access the live webcast through the provided link, and a replay will be available for those unable to attend. This event represents an opportunity for Helus Pharma to reinforce its message of innovation and patient care, potentially influencing its trajectory in the coming years.
